Sign In
Buy CUE
$26.84
-3.56 (-11.71%)
At Close: Jul 31, 2026
Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference
08:00am, Monday, 22'nd Nov 2021
CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectiv
Cue Biopharma, Inc. (NASDAQ:CUE) Shares Bought by State Street Corp
10:04am, Sunday, 21'st Nov 2021 Transcript Daily
State Street Corp raised its holdings in Cue Biopharma, Inc. (NASDAQ:CUE) by 7.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,470,075 shares of the companys stock after acquiring an additional 99,470 shares during the period. State Street Corp owned approximately []
Cue Biopharma (NASDAQ:CUE) Shares Gap Up to $16.56
10:44am, Wednesday, 17'th Nov 2021 Dakota Financial News
Cue Biopharma, Inc. (NASDAQ:CUE)s share price gapped up prior to trading on Monday . The stock had previously closed at $16.56, but opened at $20.00. Cue Biopharma shares last traded at $17.59, with a volume of 3,641 shares traded. The firm has a market capitalization of $542.16 million, a price-to-earnings ratio of -11.23 and a []
Cue Biopharma rises on data for CUE-101 in head and neck cancer
02:10pm, Monday, 15'th Nov 2021 Seeking Alpha
Cue Biopharma (NASDAQ:CUE) Stock Price Up 6.7%
07:46am, Sunday, 14'th Nov 2021 Dakota Financial News
Cue Biopharma, Inc. (NASDAQ:CUE) rose 6.7% on Friday . The stock traded as high as $16.14 and last traded at $16.09. Approximately 4,267 shares changed hands during trading, a decline of 99% from the average daily volume of 322,570 shares. The stock had previously closed at $15.08. The firms 50-day simple moving average is $13.21 []
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
08:00am, Wednesday, 10'th Nov 2021
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectiv
Analysts Estimate Cue Biopharma, Inc. (CUE) to Report a Decline in Earnings: What to Look Out for
04:02pm, Tuesday, 09'th Nov 2021
Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101
08:00am, Tuesday, 21'st Sep 2021
Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2021 Results - Earnings Call Transcript
09:40pm, Tuesday, 17'th Aug 2021
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2021 Results - Earnings Call Transcript
CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engag
Cue Biopharma to Host Business Update Call and Webcast
08:00am, Tuesday, 10'th Aug 2021
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectiv
Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference
08:00am, Tuesday, 03'rd Aug 2021
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectiv
Earnings Preview: Cue Biopharma, Inc. (CUE) Q2 Earnings Expected to Decline
04:43pm, Friday, 30'th Jul 2021
Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
08:00am, Monday, 14'th Jun 2021
CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectiv
Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting
08:30am, Thursday, 03'rd Jun 2021
CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectiv
